Global and regional epidemiological trends
(as of 28 November 2021)

Previous week:
3,799,878 new confirmed cases
47,524 new deaths

Cumulative:
260,493,573 confirmed cases
5,195,354 deaths

* Data are incomplete for the current week. Cases depicted by bars; deaths depicted by line.
EURO: Current epidemiological situation

Infections, test positivity, hospitalizations and ICU admissions continue to rise across Europe

Reported COVID-19 cases and deaths have doubled in Europe over the past 2+ months

Last week, >2.6 million new cases reported and over 29,000 new deaths reported

There are many factors contributing to the current increase in cases in the EURO region, including:

- 99% prevalence of Delta variant
- Relaxation of PHSM over many months
- Slow/light re-introduction of PHSM
- Low vaccination coverage (in some areas/countries) especially among vulnerable populations
Epidemic curves

Repeated waves

Sustained transmission

Exclusion/control not sustained
Factors driving transmission

- The virus continues to evolve resulting in more transmissible variants

- **Highly susceptible population**: Driven by unequal vaccine distribution & access to live saving tools, a large proportion of the world population remains susceptible to infection & at increased risk of severe disease and death

- **Increased social mobility and social mixing** provides increases exposure to the virus, combined with Inappropriate, inconsistent use of proven Public Health and Social Measures

- Misinformation, disinformation, conflicting messaging, politicization
Use of PHSM in the context of increasing social mobility

Haug N et al, Nat Hum Behav. 2020
Virus evolution - Genomic spread of SARS-CoV-2 VOCs

Frequencies (colored by Clade)

20I (Alpha, V1)
20A
20C
20B

21J (Delta)

Source: Nextstrain based on GISAID data nextstrain.org/ncov/global

Variants of Interest

<table>
<thead>
<tr>
<th>WHO label</th>
<th>Pango lineage*</th>
<th>GISAID clade</th>
<th>Nextstrain clade</th>
<th>Earliest documented samples</th>
<th>Date of designation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lambda</td>
<td>C.37</td>
<td>GR/452Q V1</td>
<td>21G</td>
<td>Peru, Dec-2020</td>
<td>14-Jun-2021</td>
</tr>
<tr>
<td>Mu</td>
<td>B.1.621</td>
<td>GH</td>
<td>21H</td>
<td>Colombia, Jan-2021</td>
<td>30-Aug-2021</td>
</tr>
</tbody>
</table>

Variants under Monitoring

<table>
<thead>
<tr>
<th>Pango lineage*</th>
<th>GISAID clade</th>
<th>Nextstrain clade</th>
<th>Earliest documented samples</th>
<th>Date of designation</th>
</tr>
</thead>
<tbody>
<tr>
<td>AZ.5</td>
<td>GR</td>
<td>-</td>
<td>Multiple countries, Jan-2021</td>
<td>22-Jun-2021</td>
</tr>
<tr>
<td>C.1.2</td>
<td>GR</td>
<td>-</td>
<td>South Africa, May 2021</td>
<td>01-Sep-2021</td>
</tr>
<tr>
<td>B.1.617.1</td>
<td>G452R V3</td>
<td>21B</td>
<td>India, Oct-2020</td>
<td>20-Sep-2021</td>
</tr>
<tr>
<td>B.1.529</td>
<td>GH530 V1</td>
<td>21F</td>
<td>United States of America, Nov-2020</td>
<td>20-Sep-2021</td>
</tr>
<tr>
<td>B.1.529</td>
<td>GH525K V3</td>
<td>21D</td>
<td>Multiple countries, Dec-2020</td>
<td>20-Sep-2021</td>
</tr>
<tr>
<td>B.1.600</td>
<td>GH</td>
<td>-</td>
<td>Dominican Republic, Mar-2021</td>
<td>12-Oct-2021</td>
</tr>
<tr>
<td>B.1.640</td>
<td>GH1930R</td>
<td>-</td>
<td>Republic of Congo, Sep-2021</td>
<td>22-Nov-2021</td>
</tr>
</tbody>
</table>

https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/
Virus evolution - VOC/VOIs over time by WHO Region

Proportion of VOC or VOI sequences reported among total sequences submitted over time, by WHO Region, 1 August 2020 – 15 October 2021

*Data source: GISAID Initiative
**Delta variant: Transmissibility and impact on herd immunity**

- Even with whole population vaccination coverage (100% of all ages), unlikely to achieving herd immunity threshold with a vaccine with high VE against infection (assumption here is 80%) given the properties of

  → Whole population immunization will not fully interrupt transmission; continued transmission is likely with variants


Personal communication Adam Kucharski, updated with Delta from Hodgson et al.

B.1.1.529 Variant of Concern: Omicron

Showing 3434 of 3434 genomes sampled between Dec 2019 and Nov 2021.
B.1.1.529 Variant of Concern: Omicron

Mutational profile

- Large number of mutations
  - 45-52 amino acid changes (including deletions) across the whole genome; 26-32 changes in Spike

- Some mutations are also present in Alpha, Beta, Gamma & Delta VOCs
  (Δ69-70; T95I; G142D/Δ143-145; K417N; T478K; N501Y; N655Y; N679K; P681H)

- Some mutations previously associated with:
  - impact on one specific PCR test by S-gene target failure
  - increase transmissibility
  - improve binding affinity - make it easier for virus to attach to cells
  - enable the virus to partially escape antibodies

With thanks to researchers across South Africa
Raw proportions of sequences by province in South Africa (*early data*)

Source: Analysis by WHO HQ COVID-19 analytics team | Data downloaded from GISAID on 30 Nov 2021 | Latest date of collected Omicron sample in dataset 22 Nov 2021
### B.1.1.529 Variant of Concern: Omicron

#### Severity
- Reports of cases of Omicron range from mild to severe disease.
- Too early to assess whether infection causes more or less severe disease compared to infections with other variants, including Delta.
- Preliminary data suggests that there are increasing rates of hospitalization in South Africa, but this may reflect the force of infection, rather than increased virulence.

#### Transmission
- Early data suggest an increased growth rate, but not yet know if Omicron is more transmissible compared to other VOCs, including Delta.
- Sequencing efforts have been enhanced across the region.

---

Courtesy of Lucille Blumberg, Richard Welch and Waasila Jassat – DATCOV, NICD, South Africa

[https://www.who.int/publications/m/item/enhancing-readiness-for-omicron-(b.1.1.529)-technical-brief-and-priority-actions-for-member-states](https://www.who.int/publications/m/item/enhancing-readiness-for-omicron-(b.1.1.529)-technical-brief-and-priority-actions-for-member-states)
## Omicron: impact on countermeasures

<table>
<thead>
<tr>
<th>Potential impact</th>
<th>Studies to be conducted (in progress)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Public Health and Social Measures</strong></td>
<td>Current public health measures such as wearing well-fitting masks, hand hygiene, physical distancing, improving ventilation of indoor spaces, avoiding crowded spaces, and getting vaccinated remain effective against all VOCs.</td>
</tr>
<tr>
<td><strong>Diagnostics</strong></td>
<td>PCR diagnostics continue to detect SARS-CoV-2 infection, including Omicron infection. S-gene target failure on PCR assay can be used as a proxy marker for Omicron, pending sequencing.</td>
</tr>
<tr>
<td><strong>Therapeutics</strong></td>
<td>Clinical management for patients with severe COVID-19 remains unchanged.</td>
</tr>
<tr>
<td><strong>Vaccines</strong></td>
<td>Impact on vaccines is not yet known. Omicron mutational profile of Omicron suggests the virus to partially escape antibodies. While may see more mild breakthrough infections from Omicron due to antibody escape, there may not be the same impact on severe disease – mediated by T-cells.</td>
</tr>
</tbody>
</table>

---

[Source](https://www.who.int/publications/m/item/enhancing-readiness-for-omicron-(b.1.1.529)-technical-brief-and-priority-actions-for-member-states)
COVID-19 advisory group pathway to informed decisions

Strong, multidisciplinary mechanism of external experts for evidence-based decision making

**Aim:** Monitor & assess SARS-CoV-2 variants and evaluate their impact on countermeasures, including vaccines, therapeutics, diagnostics or effectiveness of public health and social measures.

---

**Virus**

**Monitoring & surveillance**

- **TAG-VE**
  - determines where variants are circulating
  - assesses whether variants alter transmission or disease characteristics or impact vaccines, therapeutics, diagnostics or effectiveness of public health and social measures

**Vaccine**

- **R&D Blueprint for epidemics**
  - COVID-19 Vaccines Research Expert Group
  - assesses the impact of Variants of Concern on current COVID-19 vaccines
  - determines whether changes to vaccine composition are needed

**Vaccine implementation**

- **SAGE**
  - advises on vaccination policies and strategies
  - the delivery of immunization programmes

---

**World Health Organization**
Frequency and magnitude of subsequent waves will depend on multiple factors:

- Population level immunity from natural infection and/or vaccination, including
  - Extent of infection
  - Extent of vaccination
    - Vaccine characteristics and efficacy
    - Strategy and priority groups (e.g., at risk groups, by age group)
    - Extent of vaccination coverage/resistance
  - Duration of protection against severe disease/death and infection (vaccine, natural immunity)
- **Severity of disease, access to early clinical care and availability of therapeutics**
- **VOCs** emerging and circulating, and transmissibility of VOCs, properties of immune escape
- **Use of Public Health and Social Measures**, including:
  - Type of measures – identify most effective measures at lowest cost (pandemic fatigue, political/economical cost)
  - Timeliness of implementation
  - Adherence to measures

What will continue to drive future trends?
Population-level immunity

Modelled estimates of seroprevalence by WHO region, Jan 20 - Apr 21, show considerable region-to-region variation

Mar/Apr 2021 modelled seroprevalence ranged from 1.2% in WPR to 48.5% in AFR
Advice for all countries

• **Advice for all countries**
  • All countries should regularly reassess and revise national plans based on current situation and national capacities
  • Accelerate vaccine coverage in at risk populations – identify those populations who are missed and target vaccination to those most vulnerable in country
  • Intensify efforts to drive down/keep down transmission – strengthen PHSM
  • Strengthen surveillance, share data and samples, surge capacities
  • Need collective approach to better assess Omicron

• **What countries should expect in the short term**
  • Increase incidence of infection with Delta expected where PHSMs are being relaxed, regardless of vaccination rollout: need to prepare for ongoing circulation of SARS-CoV-2 and prepare for surges
  • There will be more variants, yet the impact of Omicron is not yet clear

We need to optimize our response for Delta which will benefit any future variants, including Omicron